​

Tenax Therapeutics (TENX) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

TENX Stock Forecast

Tenax Therapeutics (TENX) stock forecast, based on 9 Wall Street analysts, predicts a 12-month average price target of $4.40, with a high of $5.00 and a low of $4.00. This represents a 106.57% increase from the last price of $2.13.

- $1 $2 $3 $4 $5 $6 $7 High: $5 Avg: $4.4 Low: $4 Last Closed Price: $2.13

TENX Stock Rating

Tenax Therapeutics stock's rating consensus is Buy, based on 9 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (55.56%), 4 Hold (44.44%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 9 0 4 5 Strong Sell Sell Hold Buy Strong Buy

TENX Price Target Upside V Benchmarks

TypeNameUpside
StockTenax Therapeutics106.57%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts189
Avg Price Target$5.00$15.50$16.56
Last Closing Price$2.13$2.13$2.13
Upside/Downside134.74%627.70%677.46%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 26163--10
Aug, 2619---10
Jul, 2617---8
Jun, 2616---7
May, 2616---7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 11, 2026Chardan Capital$5.00$1.64204.88%134.74%
Aug 11, 2026Canaccord Genuity$4.00$1.38189.86%87.79%
Aug 11, 2026Guggenheim$4.00$1.38189.86%87.79%
Aug 11, 2026Leerink Partners$4.00$1.38189.86%87.79%
Aug 10, 2026Roth Capital$5.00$1.40257.14%134.74%
Jul 28, 2026Canaccord Genuity$35.00$16.19116.18%1543.19%
Jun 22, 2026Guggenheim$40.00$12.00233.33%1777.93%
Jun 22, 2026Chardan Capital$27.00$12.00125.00%1167.61%
Dec 17, 2025Guggenheim$25.00$11.16124.01%1073.71%
Sep 08, 2025Yasmeen RahimiPiper Sandler$20.00$6.04231.13%838.97%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 10, 2026Cantor FitzgeraldOverweightOverweighthold
Aug 31, 2026UBSNeutralBuyupgrade
Aug 31, 2026UBSNeutraldowngrade
Aug 31, 2026GuggenheimBuyNeutraldowngrade
Aug 11, 2026GuggenheimBuyBuyhold
Aug 10, 2026William BlairOutperformMarket Performdowngrade
Jul 22, 2026Evercore ISIOutperforminitialise
Jun 24, 2026Cantor FitzgeraldOverweightOverweighthold
Jun 22, 2026GuggenheimBuyBuyhold
Jun 01, 2026Piper SandlerOverweightOverweighthold

Financial Forecast

EPS Forecast

$-35 $-27 $-19 $-11 $-3 $5 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-31.09$-1.15$-1.34---
Avg Forecast$-31.05$-2.28$-2.70$-1.71$-1.01$-0.29
High Forecast$-28.62$-1.55$-0.62$-0.79$1.82$-0.29
Low Forecast$-33.47$-3.00$-6.79$-3.57$-4.15$-0.29
Surprise %0.13%-49.56%-50.37%---

Revenue Forecast

$0 $30M $60M $90M $120M $150M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast--$2.00M$4.16M$55.16M$113.68M
High Forecast--$2.00M$4.16M$55.16M$113.68M
Low Forecast--$2.00M$4.16M$55.16M$113.68M
Surprise %------

Net Income Forecast

$-55M $-43M $-31M $-19M $-7M $5M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-7.71M$-17.60M$-52.60M---
Avg Forecast$-7.71M$-566.34K$-920.36K$-541.41K$-289.44K$-71.22K
High Forecast$-7.11M$-386.14K$-154.58K$-195.22K$452.18K$-71.22K
Low Forecast$-8.32M$-746.54K$-1.69M$-887.60K$-1.03M$-71.22K
Surprise %0.00%3008.02%5615.07%---

TENX Forecast FAQ

Is Tenax Therapeutics stock a buy?

Tenax Therapeutics stock has a consensus rating of Buy, based on 9 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 4 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Tenax Therapeutics is a favorable investment for most analysts.

What is Tenax Therapeutics's price target?

Tenax Therapeutics's price target, set by 9 Wall Street analysts, averages $4.4 over the next 12 months. The price target range spans from $4 at the low end to $5 at the high end, suggesting a potential 106.57% change from the previous closing price of $2.13.

How does Tenax Therapeutics stock forecast compare to its benchmarks?

Tenax Therapeutics's stock forecast shows a 106.57% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Tenax Therapeutics over the past three months?

  • September 2026: 10.00% Strong Buy, 60.00% Buy, 30.00% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 10.00% Strong Buy, 90.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • July 2026: 12.50% Strong Buy, 87.50% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Tenax Therapeutics’s EPS forecast?

Tenax Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-1.71, marking a 27.61% increase from the reported $-1.34 in 2025. Estimates for the following years are $-1.01 in 2027, and $-0.29 in 2028.

What is Tenax Therapeutics’s revenue forecast?

Tenax Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $4.16M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $55.16M, and $113.68M for 2028.

What is Tenax Therapeutics’s net income forecast?

Tenax Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-541K, representing a -98.97% decrease from the reported $-52.599M in 2025. Projections indicate $-289K in 2027, and $-71.222K in 2028.